Annexon (NASDAQ:ANNX – Get Free Report) and uniQure (NASDAQ:QURE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.
Earnings & Valuation
This table compares Annexon and uniQure”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annexon | N/A | N/A | -$206.69 million | ($1.36) | -4.23 |
| uniQure | $16.10 million | 74.94 | -$198.97 million | ($3.45) | -5.54 |
Profitability
This table compares Annexon and uniQure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annexon | N/A | -101.33% | -76.96% |
| uniQure | -1,236.00% | -174.03% | -27.41% |
Analyst Recommendations
This is a summary of current ratings and target prices for Annexon and uniQure, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annexon | 1 | 1 | 5 | 0 | 2.57 |
| uniQure | 1 | 6 | 10 | 0 | 2.53 |
Annexon presently has a consensus target price of $17.00, suggesting a potential upside of 195.65%. uniQure has a consensus target price of $43.33, suggesting a potential upside of 126.52%. Given Annexon’s stronger consensus rating and higher probable upside, equities analysts clearly believe Annexon is more favorable than uniQure.
Volatility & Risk
Annexon has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
Insider and Institutional Ownership
78.8% of uniQure shares are owned by institutional investors. 12.7% of Annexon shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Annexon beats uniQure on 8 of the 13 factors compared between the two stocks.
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.
